Javelin Pharmaceuticals Announces Acceptance Of Marketing Authorization Application For European Regulatory Approval Of Dyloject(TM)
NEW YORK--(BUSINESS WIRE)--Oct. 24, 2005--Javelin Pharmaceuticals, Inc. (OTC BB: JVPH) announced today the UK Medicines and Healthcare products Regulatory Agency (MHRA) has accepted for review the Marketing Authorization Application (MAA) for Dyloject(TM) (injectable diclofenac) for the treatment of patients with postsurgical pain.